Resource Summary Report

Generated by RRID on Aug 28, 2026

SU-DHL-6

RRID:CVCL_2206
Type: Cell Line

Proper Citation

RRID:CVCL_2206

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2206

Proper Citation: RRID:CVCL_2206

Description: Cell line SU-DHL-6 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: PMID:83902, PMID:177185, PMID:214220, PMID:371794, PMID:3881165, PMID:7849311, PMID:9738977, PMID:9787181, PMID:10676951, PMID:12169673, PMID:15122589, PMID:16960149, PMID:19278952, PMID:20054396, PMID:20215515, PMID:20628145, PMID:20889926, PMID:22460905, PMID:23699601, PMID:25355872, PMID:25485619, PMID:25877200, PMID:25894527, PMID:25960936, PMID:26589293, PMID:26727417, PMID:27397505, PMID:28196595, PMID:30285677, PMID:30629668, PMID:30894373, PMID:31068700, PMID:31160637, PMID:31395879, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SU-DHL-6

Synonyms: SUDHL6, SuDHL6, SU-DHL6, SUDHL-6, SuDHL-6, Sudhl-6, SUD6, Stanford University-Diffuse Histiocytic Lymphoma-6, DHL-6, DHL6

Cross References: CLO:CLO_0037063, EFO:EFO_0002357, AddexBio:C0003011/4672, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-2959, BioSample:SAMN03471138, BioSample:SAMN10989551, cancercelllines:CVCL_2206, CCRID:5301HUM-KCB1629YJA, CCTCC:GDC0164, Cell_Model_Passport:SIDM00407, ChEMBL-Cells:CHEMBL4295461, Cosmic:687854, Cosmic:850205, Cosmic:1070712, Cosmic:1329089, Cosmic:1517640, Cosmic:1541911, Cosmic:1629935, Cosmic:1636688, Cosmic:1714158, Cosmic:2276340, Cosmic:2297009, Cosmic:2437315, Cosmic-CLP:1331037, DepMap:ACH-000611, DSMZ:ACC-572, DSMZCellDive:ACC-572, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, ENCODE:ENCBS107PVI, ENCODE:ENCBS136LHJ, ENCODE:ENCBS401ZBX, ENCODE:ENCBS782RBW, GDSC:1331037, GEO:GSM1955, GEO:GSM115975, GEO:GSM201348, GEO:GSM380147, GEO:GSM552465, GEO:GSM887655, GEO:GSM888747, GEO:GSM1035311, GEO:GSM1374908, GEO:GSM1670487, IARC_TP53:28323, IGRhCellID:SUDHL6, KCB:KCB 2016029YJ-A, LiGeA:CCLE_578, LINCS_LDP:LCL-1138, Lonza:942, MetaboLights:MTBLS774, PharmacoDB:SUDHL6_1504_2019, PRIDE:PXD000589, PRIDE:PXD030304, Progenetix:CVCL_2206, PubChem_Cell_line:CVCL_2206, Wikidata:Q54970721

ID: CVCL_2206

Record Creation Time: 20220427T221612+0000

Record Last Update: 20260815T235918+0000

Ratings and Alerts

No rating or validation information has been found for SU-DHL-6.

No alerts have been found for SU-DHL-6.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 38 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Wu J, et al. (2026) Hi-C for genome-wide detection of enhancer-hijacking rearrangements in routine lymphoid cancer biopsies. Cell genomics, 6(5), 101166.

Isoyama S, et al. (2026) Cooperative Roles of Class IA PI3K Isoforms in Translocation-Related Sarcoma Cell Survival and Proliferation. Cancer research communications, 6(4), 976.

Krishnamoorthy M, et al. (2025) Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. Frontiers in immunology, 16, 1518787.

Rossi A, et al. (2025) Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma. iScience, 28(5), 112333.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood cancer discovery, 6(6), 580.

Sahasrabuddhe AA, et al. (2025) The FBXO45-GEF-H1 Axis Controls Germinal Center Formation and B-cell Lymphomagenesis. Cancer discovery, 15(4), 838.

Peled A, et al. (2025) BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway. Research square.

Mani R, et al. (2025) TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. iScience, 28(6), 112584.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. Leukemia, 38(10), 2210.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer cell, 42(7), 1185.

McCrury M, et al. (2024) Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. Molecular cancer therapeutics, 23(3), 316.

Eiken AP, et al. (2024) Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. Cancer research communications, 4(5), 1328.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Pieper NM, et al. (2024) Inhibition of bromodomain and extra-terminal proteins targets constitutively active NF?B and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. Cell communication and signaling : CCS, 22(1), 415.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. Blood cancer discovery, 5(6), 417.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. Nature communications, 14(1), 3742.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Donati G, et al. (2022) Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma. Molecular oncology, 16(5), 1132.

Grubb T, et al. (2022) A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Antiapoptotic Protein in Kidney Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(21), 4689.